Author

A. Zoubeidi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 6 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

H. Beltran· 3 shared E. Corey· 2 shared J. Alumkal· 2 shared A. Aguda· 1 shared A. Delcourt· 1 shared A. G. Bert· 1 shared A. Jones· 1 shared A. Kaipainen· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. Beltran

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer

P. Crowell, J. Giafaglione, A. Jones, N. Nunley, T. Hashimoto, A. Delcourt, A. Petcherski, M. Bernard, R. R. Huang, J.-Y. Low, N. Matulionis, X. Guan, N. Navone, J. Alumkal, M. Haffner, , A. S. Goldstein

This study shows that androgen receptor inhibition in prostate cancer cells shifts metabolism to oxidative mitochondrial pathways and increases sensitivity to complex I inhibitors.

Cell Reports · Oct 1, 2023Peer-reviewedCancer Biology

Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer.

D. Thaper, R. Munuganti, A. Aguda, S. Kim, S.-y. Ku, O. Sivak, S. Kumar, S. Vahid, D. Ganguli, H. Beltran, C. M. Morrissey, E. Corey, A. Zoubeidi

This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.

bioRxiv · May 4, 2022 · PreprintCancer Biology

Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.

J. Monga, I. Adrianto, C. Rogers, S. Gadgeel, D. Chitale, J. Alumkal, H. Beltran, A. Zoubeidi, J. Ghosh

This study identifies Tribbles 2 as a driver of enzalutamide resistance in prostate cancer by promoting lineage plasticity and neuroendocrine differentiation.

bioRxiv · Mar 26, 2021Cancer Biology

Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation of long non-coding RNAs

E. I. J. Lelong, P. Adjibade, F.-H. Joncas, G. Khelifi, V. Grenier St-Sauveur, A. Zoubeidi, J.-P. Lambert, P. Toren, R. Mazroui, S. M. I. Hussein

This study identifies global translational deregulation and unconventional translation of long non-coding RNAs in enzalutamide-resistant prostate cancer.

bioRxiv · Jan 5, 2021 · PreprintCancer Biology

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

MicroRNA-194 promotes lineage plasticity in advanced prostate cancer

R. C. Fernandes, J. Toubia, S. Townley, A. R. Hanson, B. K. Dredge, K. A. Pillman, A. G. Bert, R. Iggo, R. Das, MURAL investigators, D. Obinata, S. Sandhu, G. P. Risbridger, R. A. Taylor, M. G. Lawrence, , L. Selth

This study identifies miR-194 as a regulator of lineage plasticity in prostate cancer by targeting FOXA1 and promoting transdifferentiation to a neuroendocrine-like state.

bioRxiv · Sep 12, 2019 · PreprintCancer Biology

Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer

R. Tiwari, N. Manzar, V. Bhatia, A. Yadav, S. Carskadon, N. Gupta, A. Zoubeidi, N. Palanisamy, B. Ateeq

This study shows that androgen deprivation therapy upregulates SPINK1, which enhances cellular plasticity and contributes to poor outcomes in prostate cancer.

bioRxiv · Feb 27, 2019Cancer Biology